148 related articles for article (PubMed ID: 37908765)
1. MRI phenotypes of glioblastomas early after treatment are suggestive of overall patient survival.
Schmitz-Abecassis B; Dirven L; Jiang J; Keller JA; Croese RJI; van Dorth D; Ghaznawi R; Kant IMJ; Taphoorn MJB; van Osch MJP; Koekkoek JAF; de Bresser J
Neurooncol Adv; 2023; 5(1):vdad133. PubMed ID: 37908765
[TBL] [Abstract][Full Text] [Related]
2. Validation of multiparametric MRI based prediction model in identification of pseudoprogression in glioblastomas.
de Godoy LL; Mohan S; Wang S; Nasrallah MP; Sakai Y; O'Rourke DM; Bagley S; Desai A; Loevner LA; Poptani H; Chawla S
J Transl Med; 2023 Apr; 21(1):287. PubMed ID: 37118754
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Prediction Based on Dynamic Contrast-Enhanced MRI and Dynamic Susceptibility Contrast-Enhanced MRI Parameters from Non-Enhancing, T2-High-Signal-Intensity Lesions in Patients with Glioblastoma.
Jo SW; Choi SH; Lee EJ; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH
Korean J Radiol; 2021 Aug; 22(8):1369-1378. PubMed ID: 33987994
[TBL] [Abstract][Full Text] [Related]
4. Differentiating Tumor Progression from Pseudoprogression in Patients with Glioblastomas Using Diffusion Tensor Imaging and Dynamic Susceptibility Contrast MRI.
Wang S; Martinez-Lage M; Sakai Y; Chawla S; Kim SG; Alonso-Basanta M; Lustig RA; Brem S; Mohan S; Wolf RL; Desai A; Poptani H
AJNR Am J Neuroradiol; 2016 Jan; 37(1):28-36. PubMed ID: 26450533
[TBL] [Abstract][Full Text] [Related]
5. Early postoperative tumor progression predicts clinical outcome in glioblastoma-implication for clinical trials.
Merkel A; Soeldner D; Wendl C; Urkan D; Kuramatsu JB; Seliger C; Proescholdt M; Eyupoglu IY; Hau P; Uhl M
J Neurooncol; 2017 Apr; 132(2):249-254. PubMed ID: 28101701
[TBL] [Abstract][Full Text] [Related]
6. Assessment of treatment response to dendritic cell vaccine in patients with glioblastoma using a multiparametric MRI-based prediction model.
de Godoy LL; Chawla S; Brem S; Wang S; O'Rourke DM; Nasrallah MP; Desai A; Loevner LA; Liau LM; Mohan S
J Neurooncol; 2023 May; 163(1):173-183. PubMed ID: 37129737
[TBL] [Abstract][Full Text] [Related]
7. Voxel-based evidence of perfusion normalization in glioblastoma patients included in a phase I-II trial of radiotherapy/tipifarnib combination.
Ken S; Deviers A; Filleron T; Catalaa I; Lotterie JA; Khalifa J; Lubrano V; Berry I; Péran P; Celsis P; Moyal EC; Laprie A
J Neurooncol; 2015 Sep; 124(3):465-73. PubMed ID: 26189058
[TBL] [Abstract][Full Text] [Related]
8. MRI and
Wirsching HG; Roelcke U; Weller J; Hundsberger T; Hottinger AF; von Moos R; Caparrotti F; Conen K; Remonda L; Roth P; Ochsenbein A; Tabatabai G; Weller M
Clin Cancer Res; 2021 Jan; 27(1):179-188. PubMed ID: 32967939
[TBL] [Abstract][Full Text] [Related]
9. Magnetic resonance perfusion for differentiating low-grade from high-grade gliomas at first presentation.
Abrigo JM; Fountain DM; Provenzale JM; Law EK; Kwong JS; Hart MG; Tam WWS
Cochrane Database Syst Rev; 2018 Jan; 1(1):CD011551. PubMed ID: 29357120
[TBL] [Abstract][Full Text] [Related]
10. Vascular architecture mapping for early detection of glioblastoma recurrence.
Stadlbauer A; Eyüpoglu I; Buchfelder M; Dörfler A; Zimmermann M; Heinz G; Oberndorfer S
Neurosurg Focus; 2019 Dec; 47(6):E14. PubMed ID: 31786560
[TBL] [Abstract][Full Text] [Related]
11. High-resolution blood-pool-contrast-enhanced MR angiography in glioblastoma: tumor-associated neovascularization as a biomarker for patient survival. A preliminary study.
Puig J; Blasco G; Daunis-I-Estadella J; Alberich-Bayarri A; Essig M; Jain R; Remollo S; Hernández D; Puigdemont M; Sánchez-González J; Mateu G; Wintermark M; Pedraza S
Neuroradiology; 2016 Jan; 58(1):17-26. PubMed ID: 26438560
[TBL] [Abstract][Full Text] [Related]
12. Three-dimensional echo planar spectroscopic imaging for differentiation of true progression from pseudoprogression in patients with glioblastoma.
Verma G; Chawla S; Mohan S; Wang S; Nasrallah M; Sheriff S; Desai A; Brem S; O'Rourke DM; Wolf RL; Maudsley AA; Poptani H
NMR Biomed; 2019 Feb; 32(2):e4042. PubMed ID: 30556932
[TBL] [Abstract][Full Text] [Related]
13. Leakage decrease detected by dynamic susceptibility-weighted contrast-enhanced perfusion MRI predicts survival in recurrent glioblastoma treated with bevacizumab.
Hilario A; Sepulveda JM; Hernandez-Lain A; Salvador E; Koren L; Manneh R; Ruano Y; Perez-Nuñez A; Lagares A; Ramos A
Clin Transl Oncol; 2017 Jan; 19(1):51-57. PubMed ID: 27026567
[TBL] [Abstract][Full Text] [Related]
14. Uninterpretable Dynamic Susceptibility Contrast-Enhanced Perfusion MR Images in Patients with Post-Treatment Glioblastomas: Cross-Validation of Alternative Imaging Options.
Heo YJ; Kim HS; Park JE; Choi CG; Kim SJ
PLoS One; 2015; 10(8):e0136380. PubMed ID: 26296086
[TBL] [Abstract][Full Text] [Related]
15. Pseudoprogression in patients with glioblastoma: added value of arterial spin labeling to dynamic susceptibility contrast perfusion MR imaging.
Choi YJ; Kim HS; Jahng GH; Kim SJ; Suh DC
Acta Radiol; 2013 May; 54(4):448-54. PubMed ID: 23592805
[TBL] [Abstract][Full Text] [Related]
16. [Prediction of clinical course of glioblastomas by MRI during radiotherapy].
Leitzen C; Schild HH; Bungart B; Herrlinger U; Lütter C; Müdder T; Wilhelm-Buchstab T; Schüller H
Strahlenther Onkol; 2010 Dec; 186(12):681-6. PubMed ID: 21221885
[TBL] [Abstract][Full Text] [Related]
17. Interstitial Photodynamic Therapy of Glioblastomas: A Long-Term Follow-up Analysis of Survival and Volumetric MRI Data.
Foglar M; Aumiller M; Bochmann K; Buchner A; El Fahim M; Quach S; Sroka R; Stepp H; Thon N; Forbrig R; Rühm A
Cancers (Basel); 2023 May; 15(9):. PubMed ID: 37174068
[TBL] [Abstract][Full Text] [Related]
18. Added value of amide proton transfer imaging to conventional and perfusion MR imaging for evaluating the treatment response of newly diagnosed glioblastoma.
Park KJ; Kim HS; Park JE; Shim WH; Kim SJ; Smith SA
Eur Radiol; 2016 Dec; 26(12):4390-4403. PubMed ID: 26883333
[TBL] [Abstract][Full Text] [Related]
19. Prediction of survival and progression in glioblastoma patients using temporal perfusion changes during radiochemotherapy.
Larsson C; Groote I; Vardal J; Kleppestø M; Odland A; Brandal P; Due-Tønnessen P; Holme SS; Hope TR; Meling TR; Fosse E; Emblem KE; Bjørnerud A
Magn Reson Imaging; 2020 May; 68():106-112. PubMed ID: 32004711
[TBL] [Abstract][Full Text] [Related]
20. Perfusion MRI in the evaluation of cerebral blood volume and mean transit time in untreated and recurrent glioblastomas.
Principi M; Italiani M; Ottaviano P
Neuroradiol J; 2009 Mar; 22(1):48-57. PubMed ID: 24206953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
